Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain. METHODS: of body-surface area) plus at least one other cardiovascular risk factor. Participants were randomly assigned in a 1:1:1 ratio to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo. Randomization was stratified according to use of sodium-glucose cotransporter 2 inhibitors. The primary outcome was the first major adverse cardiovascular event (MACE; a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes). RESULTS: A total of 4076 participants were enrolled; 2717 were assigned to receive efpeglenatide and 1359 to receive placebo. During a median follow-up of 1.81 years, an incident MACE occurred in 189 participants (7.0%) assigned to receive efpeglenatide (3.9 events per 100 person-years) and 125 participants (9.2%) assigned to receive placebo (5.3 events per 100 person-years) (hazard ratio, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P<0.001 for noninferiority; P = 0.007 for superiority). A composite renal outcome event (a decrease in kidney function or macroalbuminuria) occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79; P<0.001). Diarrhea, constipation, nausea, vomiting, or bloating occurred more frequently with efpeglenatide than with placebo. CONCLUSIONS: In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo. (Funded by Sanofi; AMPLITUDE-O ClinicalTrials.gov number, NCT03496298.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effects of semaglutide on albuminuria and eGFR observed in the present STEP analysis are consistent with post hoc analyses of other GLP-1RA clinical trials.”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging data suggest that use of both classes of drugs will provide an additive cardiovascular and kidney outcomes benefit;”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [270]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over a median follow-up of 1.8 years, efpeglenatide therapy reduced the risk of incident major adverse cardiovascular events by 27% and of a composite renal outcome event by 32%.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“Some GLP-1RAs [albiglutide, efpeglenatide, dulaglutide, liraglutide and once-weekly (OW) semaglutide] reduce the risk of major adverse CV events (MACE) in people with T2D with established CVD or at high risk of CVD [6][7][8][9][10].”
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Self-citationType 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., Deanfield, J., Smeeth, L., Timmis, A., & Hemingway, H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70219-0 · Cited by 1,225
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Matsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., Guallar, E., Jafar, T., Jassal, S. K., Landman, G. W. D., Muntner, P., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00040-6 · Cited by 903
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Self-citationLaiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Cited by
Items 201–300 of 873
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
Singh, A. K., & Singh, R. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i6.329 · Cited by 35
Wu, Q., Li, D., Huang, C., Zhang, G., Wang, Z., Liu, J., Yu, H., Song, B., Zhang, N., Li, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113517 · Cited by 34
Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M. W., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40060 · Cited by 38
Sohn, M., Dietrich, J. W., Nauck, M. A., & Lim, S. K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01877-6 · Cited by 34
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
“Data were extracted from articles reporting primary results for the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) [21], LEADER [17], SUSTAIN-6 [18], EXSCEL [23], Harmony Outcomes [19], REWIND [25], PIONEER 6 [22], AMPLITUDE-O [20] and FREEDOM CVO [24] trials, sorted by publication date, and from the me…”
BackgroundMethodInfluentialTuttle, K. R., Bain, S. C., Bosch‐Traberg, H., Khunti, K., Rasmussen, S., Sokareva, E., & Cherney, D. Z. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.04.028 · Cited by 37
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 35
Ferreira, J. P., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2660 · Cited by 32
der Beek, A. B. V. D. A., Apperloo, E. M., Jongs, N., Rouw, D. B., Sjöström, C. D., Friedli, I., Johansson, L., van Raalte, D. H., Hoogenberg, K., & Heerspink, H. J. L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15033 · Cited by 32
Krisanapan, P., Sanpawithayakul, K., Pattharanitima, P., Thongprayoon, C., Miao, J., Mao, M. A., Suppadungsuk, S., Tangpanithandee, S., Craici, I. M., & Cheungpasitporn, W. (2024) · Diseases · doi:10.3390/diseases12010014 · Cited by 36
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
Berndt, J., Ooi, S. L., & Pak, S. C. (2021) · Molecules · doi:10.3390/molecules26164822 · Cited by 33
He, W., Wei, J., Liu, X., Zhang, Z., Huang, R., & Jiang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-62465-6 · Cited by 30
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Agrawal, V., Amasa, S., Karabacak, M., & Margetis, K. D. (2024) · Neurosurgery · doi:10.1227/neu.0000000000003291 · Cited by 34
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 34
Li, X., Song, Y., Guo, T., Xiao, G., & Li, Q. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101366 · Cited by 33
Villaschi, A., Ferrante, G., Cannata, F., Pini, D., Pagnesi, M., Corrada, E., Reimers, B., Mehran, R., Federici, M., Savarese, G., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02362-6 · Cited by 31
Wang, T., Ding, J., Cheng, X., Yang, Q., & Hu, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1396656 · Cited by 34
Chen, X., Zhang, X., Xiang, X., Fang, X., & Feng, S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01497-4 · Cited by 32
Tang, A. S. P., Hsu, J. T. Y., Chong, S. K. S., Quek, J., Shek, G., Sulaimi, F., Chan, K. E., Anand, V. V., Chong, B., Mehta, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02840-3 · Cited by 29
Gerstein, H. C., Li, Z., Ramasundarahettige, C. F., Baek, S. J., Branch, K. R., Prato, S. D., Lam, C. S. P., Lópes, R. D., Pratley, R. E., Rosenstock, J., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063716 · Cited by 29
Self-citationHuang, S., Chen, L., & Hsiao, F. (2023) · Age and Ageing · doi:10.1093/ageing/afad128 · Cited by 29
Małyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 30
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13609 · Cited by 31
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Sardu, C., Marfella, L. V., Rinaldi, L., Sasso, F. C., Cozzolino, D., Nappo, F., Sellitto, A., Romano, C. P., Carusone, C., D’Onofrio, N., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112452 · Cited by 30
Liarakos, A. L., Tentolouris, A., Kokkinos, A. D., Eleftheriadou, I., & Tentolouris, N. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108390 · Cited by 30
Cai, H., Chen, Q., Duan, Y., Zhao, Y., & Zhang, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1106868 · Cited by 29
Moiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpaf205 · Cited by 26
Ghafoury, R., Malek, M., Ismail‐Beigi, F., & Khamseh, M. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01743-6 · Cited by 31
Gómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 27
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
Stone, C. R., Harris, D. D., Broadwin, M., Kanuparthy, M., Nho, J.-W., Yalamanchili, K., Hamze, J., Abid, M. R., & Sellke, F. W. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321850 · Cited by 26
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Sattar, N. A., Gerstein, H. C., D’Alessio, D. A., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., et al. (2026) · Diabetes Care · doi:10.2337/dc26-0298 · Cited by 26
Self-citationYeong, T. J. J., Mai, A. S., Lim, O. Z.-H., Ng, C. H., Chin, Y. H., Tay, P. W. L., Lin, C., Muthiah, M. D., Khoo, C. M., Dalakoti, M., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13822 · Cited by 25
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
Aboolian, A., Urner, S., Roden, M., Jha, J. C., & Jandeleit-Dahm, K. A. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_576 · Cited by 28
GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
de Mortanges, A. P., Sinaci, E., Salvador, D., Bally, L., Muka, T., Wilhelm, M., & Bano, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856111 · Cited by 26
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 27
Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease
Zhang, C., Shi, Y., Liu, C., Sudesh, S. M., Zhao, H., Li, P., Liu, Q., Ma, Y., Shi, A., & Cai, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02273-4 · Cited by 32
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Caturano, A., Galiero, R., Rocco, M. P., Tagliaferri, G., Piacevole, A., Nilo, D., Lorenzo, G. D., Sardu, C., Vetrano, E., Monda, M., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092039 · Cited by 27
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 25
Siddiqui, H. F., Waqas, S. A., Batool, R. M., Salim, H., Minhas, A. M. K., Hasni, S. F., Alsaid, A., Sannino, A., Afzal, A. M., & Khan, M. S. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10523-0 · Cited by 25
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 37
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
Nissen, S. E., Wolski, K., D’Alessio, D. A., Weerakkody, G. J., Kiljanski, J. I., Wiese, R. J., Pavo, I. J., Cariou, B., & Nicholls, S. J. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0767 · Cited by 25
Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease
Chen, X., Dai, W., Li, H., Yan, Z., Liu, Z., & He, L. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2160518 · Cited by 27
Kimura, T., Katakura, Y., Shimoda, M., Kawasaki, F., Yamabe, M., Tatsumi, F., Matsuki, M., Iwamoto, Y., Anno, T., Fushimi, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15258 · Cited by 28
Preventing new-onset heart failure: Intervening at stage A
Upadhya, B., Hegde, S., Tannu, M., Stacey, R. B., Kalogeropoulos, A. P., & Schocken, D. D. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100609 · Cited by 27
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Connelly, K. A., O’Meara, E., Zieroth, S. R., & Sherifali, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02154-w · Cited by 29
Pan, S., Su, E.-L., Huang, C., Chuang, S., Chiang, C., Chen, C., & Cheng, H. (2024) · Age and Ageing · doi:10.1093/ageing/afae175 · Cited by 25
Lecis, D., Prandi, F. R., Barone, L., Belli, M., Sergi, D., Longo, S., Muscoli, S., Romeo, F., Federici, M., Lerakis, S., et al. (2023) · Biomolecules · doi:10.3390/biom13121695 · Cited by 23
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., Deng, X., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehaf1066 · Cited by 24
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22
Shetty, S., Suvarna, R., Awasthi, A., Bhojaraja, M. V., & Pappachan, J. M. (2025) · Diagnostics · doi:10.3390/diagnostics15080973 · Cited by 25
Exploring molecular targets in diabetic kidney disease
Maruno, S., Tanaka, T., & Nangaku, M. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.251 · Cited by 24
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Lewis, R., Jovkovic, M., Zieroth, S. R., O’Meara, E., Connelly, K. A., & Sherifali, D. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.05.011 · Cited by 26
Recent advances in the treatment of patients with obesity and chronic kidney disease
Wahab, R. A., COHEN, R. V., & le Roux, C. W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2203517 · Cited by 25
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 23
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Trevella, P., Ekinci, E. I., & MacIsaac, R. J. (2024) · Nephrology · doi:10.1111/nep.14336 · Cited by 27
The role of hypoxia-inducible factors 1 and 2 in the pathogenesis of diabetic kidney disease
Kleibert, M., Tkacz, K., Winiarska, K., Małyszko, J., & Cudnoch‐Jędrzejewska, A. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02152-x · Cited by 22
Fan, S., Qiu, Y., Liu, J., Zhu, T., Wang, C., Liu, D., Yan, L., & Ren, M. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16242 · Cited by 21
Upcoming drug targets for kidney protective effects in chronic kidney disease
Nardone, M., Yau, K., Kugathasan, L., Odutayo, A., Mohsen, M., Ouimet, J.-P., Sridhar, V. S., & Cherney, D. Z. I. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae216 · Cited by 25
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 23
Liu, Q., Guo, S., Tong, Y., Li, Q., Baoxiang, Z., Wang, J., Wang, Y., Gao, W., & Zou, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70220 · Cited by 21
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
New Approaches to Cardiovascular Disease and Its Management in Kidney Transplant Recipients
Aziz, F., Jorgenson, M., Garg, N., Parajuli, S., Mohamed, M., Raza, F., Mandelbrot, D. A., Djamali, A., & Dhingra, R. (2021) · Transplantation · doi:10.1097/tp.0000000000003990 · Cited by 23
Evans, M., Chandramouli, A. S., Faurby, M. D., Matthiessen, K. S., Mogensen, P. B., & Verma, S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14703 · Cited by 21
Li, J., Cheng, J., Zhang, W., Lan, L., & Ge, W. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108362 · Cited by 24
Ngoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 24
Zhang, X., & Marx, C. M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.3.276 · Cited by 24
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 24
Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
Shi, S., Chen, X., Yu, W., Ke, X., & Ma, T. (2023) · Endocrine Connections · doi:10.1530/ec-23-0284 · Cited by 21
Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment
Deng, W.-Y., Zhao, Z., Zou, T., Kuang, T.-D., & Wang, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421527 · Cited by 23
Krychtiuk, K. A., Marquis‐Gravel, G., Murphy, S., Alexander, K. P., Chiswell, K., Green, J. B., Leiter, L. A., Lópes, R. D., Prato, S. D., Jones, W. S., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae006 · Cited by 21
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 22
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression
Holliday, M. W., Frost, L. A., & Navaneethan, S. D. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000976 · Cited by 22
Mendonça, L., Moura, H., Castro‐Chaves, P., Neves, J. S., & Ferreira, J. P. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000584 · Cited by 21
McIntyre, R. S., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430306 · Cited by 22
Sattar, N., Deanfield, J., & Delles, C. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac186 · Cited by 20
Self-citationRADAKRISHNAN, A., AGRAWAL, S., SINGH, N., Barbieri, A., Shaw, L. J., Gulati, M., & Lala, A. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.01.008 · Cited by 23
Siddiqui, H. F., Ali, D., Sajid, M., Qureshi, S., Siddiqui, H., Hasan, A., Ripley, D. P., Ahmed, R., & Waqas, S. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70123 · Cited by 22
González-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 23
New Horizons: Emerging Antidiabetic Medications
Mingrone, G., Castagneto‐Gissey, L., & Bornstein, S. R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac499 · Cited by 22
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 22
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Chatzianagnostou, K., Gaggini, M., Suman, A. F., Simonini, L., & Vassalle, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116218 · Cited by 23
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia
Novodvorský, P., & Haluzík, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00982-3 · Cited by 21
Wanner, C., Zhao, M., Amin, A., Nicola, L. D., Sauer, A. J., Allum, A. M., Aranda, U., Nam, Y., & Butler, J. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03228-1 · Cited by 23
Incretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Targeting NF-κB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents
Abhirami, B. L., Krishna, A. A., Kumaran, A., & Chiu, C. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01555-z · Cited by 22
Siddiqi, T. J., Khan, M. S., Waqas, S. A., Spall, H. G. C. V., Shapiro, M. D., Fonarow, G. C., Januzzi, J. L., Afzal, A. M., Pandey, A., Butler, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70048 · Cited by 20
Bakkar, N. Z., AlZaim, I., & EL‐Yazbi, A. F. (2022) · Clinical Science · doi:10.1042/cs20220404 · Cited by 20
Avdic, T., Carlsen, H. K., Rawshani, A., Guðbjörnsdóttir, S., Mandalenakis, Z., & Eliasson, B. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02226-x · Cited by 21
Strategies for chronic coronary disease: A brief guide for clinicians
Krittanawong, C., Khawaja, M., Virk, H. U. H., Escobar, J., Khalid, U., Birnbaum, Y., Lavie, C. J., Sharma, S. K., Jneid, H. M., Rao, S. V., et al. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00006-w · Cited by 21
Metadata
- Authors
- Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., Dyal, L., & Branch, K.
- Affiliations
- University of Pisa (IT)
- From the Population Health Research Institute, Hamilton Health Sciences (H.C.G., C.R., L.H., L.D.), and McMaster University (H.C.G.) — both in Hamilton, ON, Canada; the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (N.S.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); AdventHealth Translational Research Institute, Orlando, FL (R.P.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.); National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); Sanofi, Bridgewater, NJ (N.S.K.); the Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy (S.D.P.); and the Division of Cardiology, University of Washington, Seattle (K.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-02
- Volume
- 385
- Issue
- 10
- Pages
- 896-907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177365549
- Cited by
- 829
- References
- 29
- Citations by year
- 2026: 150 · 2025: 187 · 2024: 159 · 2023: 149 · 2022: 136 · 2021: 47
- FWCI
- 91.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- efpeglenatide, type 2 diabetes, GLP-1 receptor agonists, exendin-4, major adverse cardiovascular events, cardiovascular risk, renal outcomes, renal function decline, macroalbuminuria, SGLT2 inhibitors, gastrointestinal adverse effects, non-inferiority, cardiovascular disease history, kidney disease, cardiovascular risk factors, myocardial infarction
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Kidney Diseases, Male, Middle Aged, Proline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
